We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Recce Pharmaceuticals is a biotechnology business based in Australia. Recce Pharmaceuticals shares (RCE) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Recce Pharmaceuticals has a trailing 12-month revenue of around $997,333. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Best Overall Broker
Our top pick for
Best low-cost broker
| 52-week range | $0.74 - $1.38 |
|---|---|
| 50-day moving average | $0.8982 |
| 200-day moving average | $0.9611 |
| Target price | N/A |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.053 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.8
| 1 week (2022-05-12) | 3.90% |
|---|---|
| 1 month (2022-04-22) | -10.61% |
| 3 months (2022-02-22) | -20.00% |
| 6 months (2021-11-22) | -10.61% |
| 1 year (2021-05-21) | -23.44% |
|---|---|
| 2 years (2020-05-22) | 37.93% |
| 3 years (2019-05-22) | 272.09% |
| 5 years (2017-05-22) | 290.24% |
| Revenue TTM | $997,333 |
|---|---|
| Gross profit TTM | $-4,067,212 |
| Return on assets TTM | -24.88% |
| Return on equity TTM | -42.75% |
| Profit margin | 0% |
| Book value | 0.117 |
| Market capitalisation | $141.4 million |
TTM: trailing 12 months
We're not expecting Recce Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Recce Pharmaceuticals 's shares have ranged in value from as little as $0.74 up to $1.38. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Recce Pharmaceuticals 's is 1.3431. This would suggest that Recce Pharmaceuticals 's shares are more volatile than the average for this exchange and represent, relatively speaking, a higher risk (but potentially also market-beating returns).
Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic anti?infectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Everything we know about the OD6 Metals IPO, plus information on how to buy in.
Steps to owning and managing Winton Land shares.
Everything we know about the Summit Minerals IPO, plus information on how to buy in.
The picks and shovels approach is one way to gain exposure to the crypto market. Here is an ETF you could consider.
Everything we know about the Regener8 Resources IPO, plus information on how to buy in.
While crypto ETFs remain a relatively new concept, here is how you can invest in one of the first physically back Bitcoin ETFs.
Here is your how to guide on buying the first Ethereum backed ETF in Australia.
Everything we know about the Southern Palladium Limited IPO, plus information on how to buy in.
Everything we know about the Coolabah Metals IPO, plus information on how to buy in.
